Recursion Pharmaceuticals (RXRX) Change in Cash (2020 - 2026)

Recursion Pharmaceuticals' Change in Cash history runs 7 years deep, the most recent figure standing at -$88.7 million for Q1 2026.

• Quarterly Change in Cash rose 5.46% year-over-year to -$88.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156.0 million (down 23.14% YoY) and the FY2025 annual result came in at $150.9 million, down 25.15% from the prior year.
• Change in Cash was -$88.7 million for Q1 2026 at Recursion Pharmaceuticals, down from $86.8 million in the prior quarter.
• Across five years, Change in Cash topped out at $222.8 million in Q1 2022 and bottomed at -$95.3 million in Q1 2024.
• A 5-year average of $21.8 million and a median of $780000.0 in 2022 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2023 — Change in Cash plunged 2615.0% — and 2024, when it soared 3863.8%.
• Recursion Pharmaceuticals' Change in Cash stood at $94.2 million in 2022, then sank by 95.52% to $4.2 million in 2023, then surged by 3863.8% to $167.2 million in 2024, then plunged by 48.1% to $86.8 million in 2025, then plunged by 202.26% to -$88.7 million in 2026.
• Business Quant data shows RXRX's Change in Cash at -$88.7 million in Q1 2026, $86.8 million in Q4 2025, and $133.3 million in Q3 2025.